Abstract
Acute profound thrombocytopenia may be associated with the administration of eptifibatide, a glycoprotein antagonist. A case report of a 61-year-old male is presented. The reported incidence of acute profound thrombocytopenia associated with eptifibatide is 0.1% to 1.0% and usually occurs within 24 hours following therapy. However, cases of profound thrombocytopenia have been reported to occur within 1 to 4 hours following infusion. Platelet counts should be monitored in patients receiving eptifibatide at least within 24 hours and preferably within 2 to 4 hours after administration. Submitted 5.8.06 | Revisions Received 6.28.06 | Accepted 7.17.06
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callSimilar Papers
More From: Laboratory Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
